ArticleScientific reports2019
Photodynamic effect of Zirconium phosphate biocompatible nano-bilayers containing methylene blue on cancer and normal cells.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 36 citations in OpenAlex.
- Immobilization of Alendronate on Zirconium Phosphate Nanoplatelets.Nanomaterials (Basel, Switzerland) · 2023Article
- Nanolayered Metal Phosphates as Biocompatible Reservoirs for Antimicrobial Silver Nanoparticles.Materials (Basel, Switzerland) · 2021Article
- Preparation of Zirconium Hydrogen Phosphate Coatings on Sandblasted/Acid-Etched Titanium for Enhancing Its Osteoinductivity and Friction/Corrosion Resistance.International journal of nanomedicine · 2021Article
- Fabrication of Anisotropic Cu Ferrite-Polymer Core-Shell Nanoparticles for Photodynamic Ablation of Cervical Cancer Cells.Nanomaterials (Basel, Switzerland) · 2020Article
- Surface-functionalised hybrid nanoparticles for targeted treatment of cancer.IET nanobiotechnology · 2020Review
- Molecular interaction and cellular studies on combination photodynamic therapy with rutoside for melanoma A375 cancer cells: an in vitro study.Cancer cell international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceutical applications of methylene blue, especially as photosensitizer, have been limited due to its rapid enzymatic reduction in the biological systems. In this study nano-platelet zirconium phosphate was synthesized and its biocompatibility was evaluated. The synthesized material was considered as drug delivery vehicle for methylene blue to enhance the photodynamic therapy efficacy in human breast cancer cells. Zirconium phosphate-methylene blue nano-hybrids were characterized by X-Ray Powder Diffraction (XRPD), Scanning Electron Microscopy (SEM), and Thermo gravimetric Analysis (TGA). Biocompatibility of synthesized nano materials were studied on Hu02 human fibroblast normal cell and MDA-MB-231 human breast cancer cell. The results clarified that ZrP-MB nanoparticles could decrease the dark toxicity of free methylene blue. Photodynamic therapy using zirconium phosphate-methylene blue on MDA-MB-231 human breast cancer was evaluated by MTT assay, colony forming ability assay, AO/EB dual staining and flow cytometry detection of apoptosis. The results suggest that zirconium phosphate-methylene blue nano-hybrids significantly enhance photodynamic therapy efficacy probably via apoptosis cell death mechanism against human breast cancer cells. According to the results, zirconium phosphate nanoparticles could be suggested as a promising nano-carrier for photosensitizer delivery in photodynamic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.